The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena
Research Funding - Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; AstraZeneca; BMS; Genentech/Roche
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Merck Serono
 
Vagif Atduev
No Relationships to Disclose
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Miguel Ángel Climent
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai Europe; EUSA Pharma; Ipsen; Janssen; Merck; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Eisai; EUSA Pharma; Janssen Oncology; Janssen-Cilag; Merck; MSD Oncology; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Bayer; Ipsen; Janssen; Merck; Pfizer; Roche
 
David William Pook
Honoraria - Bayer; Merck/Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck/Pfizer; Merck/Pfizer; Pfizer
 
Piotr Tomczak
No Relationships to Disclose
 
Philippe Barthelemy
Honoraria - Astellas Pharma; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; SEAGEN
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Research Funding - IPSEN (Inst)
Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Taron Nalbandian
Research Funding - Janssen; MSD; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; IPSEN,
 
Viktor Stus
Honoraria - Astellas Pharma; Bionorica; Kyiv Vitamin Plant; LLC; PrJSC; Representation; Stada
Research Funding - Merck
 
Thomas Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bayer
 
Pawel Wiechno
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; MSD; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Erhan Gokmen
Stock and Other Ownership Interests - Immunogen; macrogenics
Honoraria - Abdi Ibrahim; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Celgene; Genekor; Gilead Sciences; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Sandoz-Novartis
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; genekor; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pfizer; Roche
 
Louis Lacombe
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Celgene (Inst); IMV (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Telix Pharmaceuticals (Inst)
 
Craig Gedye
Leadership - Anzup; COGNO; International Kidney Cancer Coalition (IKCC); MHF; SAC for BCBA
Consulting or Advisory Role - Alloplex Biotherapeutics Inc; BCAL Diagnostics; Cadex Genomics
 
Joseph E. Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
 
Manish Sharma
Employment - Merck
 
Jerry Cornell
Employment - Merck
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer